Table 2. Matching weight-adjusted incidence rates and hazard ratios for the primary and secondary outcomes among inpatient Veterans with treated hypertension who were current users of an ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen and ARB user vs. ACEI user, separately.
| ARB/ACEI- vs. non-ARB/ACEI-based antihypertensive regimen comparison* (n = 485) | ARB user vs. ACEI user comparison (n = 3,178) | |||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | ARB/ACEI | Non-ARB/ACEI | Hazard Ratio | ARB | ACEI | Hazard Ratio | ||
| (n = 210) | (n = 275) | (95% CI) | p-value | (n = 1,164) | (n = 2,014) | (95% CI) | p-value | |
| Primary Outcome | ||||||||
| All-cause mortality | 8 (3.4) | 6 (2.0) | 1.25 (0.30–5.13) | 0.76 | 168 (21.0) | 242 (17.7) | 1.13 (0.93–1.38) | 0.23 |
| Secondary Outcomes | ||||||||
| ICU admission | 48 (33.0) | 40 (19.5) | 1.05 (0.54–1.94) | 0.94 | 264 (26.4) | 497 (24.5) | 0.92 (0.79–1.08) | 0.29 |
| Dialysis | 0 (0.0) | 2 (0.2) | n/a | n/a | 33 (4.6) | 448 (4.5) | 1.08 (0.84–1.40) | 0.54 |
| Mechanical ventilation | 11 (4.8) | 16 (5.9) | 0.67 (0.22–2.03) | 0.47 | 185 (24.5) | 313 (23.9) | 0.96 (0.80–1.15) | 0.65 |
Numbers in table are expressed as unweighted frequency of event (weighted rate per 100 person-months).
*Exploratory due to small sample size.
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CI: confidence interval; ICU: intensive care unit